Immortal Dragons founder explains how a purpose-driven investment philosophy can help accelerate longevity breakthroughs.
The latest investor to join Longevity.Technology’s current seed investment round is Immortal Dragons, a “purpose-driven” longevity investment fund headquartered in Singapore. The fund’s philosophy is rooted in the belief that aging and death are not immutable destinies, but technical challenges that can be addressed through scientific breakthroughs.
In addition to its investments in longevity biotech moonshots and supporting infrastructure, Immortal Dragons also focuses on evangelism and community building. This is reflected by its latest investment in Longevity.Technology, which was founded on the belief that the future of healthspan innovation depends not just on science, but on infrastructure, intelligence and access.
“We’ve worked to unify what was a fragmented sector back in 2019, by building a platform that empowers investors, founders and researchers with the insight they need to turn promise into progress,” said Longevity.Technology founder Phil Newman. “Our partnership with Immortal Dragons marks a powerful next chapter in the journey of the longevity industry toward the megatrend we all know it will be.”
Investors interested in joining our seed round can let us know below.
Longevity.Technology: Unlike conventional venture capital firms that focus purely on financial returns, Immortal Dragons distinguishes itself by prioritizing meaningful advancements in human longevity and healthspan over economic gain. This conviction drives the fund to support projects that are often considered too radical or high-risk by mainstream investors, focusing on transformative rather than incremental change in the longevity sector. We sat down with Immortal Dragons’ founder Boyang Wang to learn more about the fund’s philosophy.
With a background in tech entrepreneurship and a lifelong fascination with existence, survival and consciousness, Boyang built Immortal Dragons to challenge the premise that aging and death are inevitable.
“I’ve never reconciled with the idea that aging and death are inevitable or that we should accept the suffering that comes with age-related diseases,” he says, suggesting these are not immutable facts of life but technical challenges that scientific innovation can solve. “The challenges of aging and disease are engineering problems that humanity can and shall overcome.”
Aging is an engineering problem
Boyang believes human society has reached a pivotal point where efforts towards extending human lifespan and improving health could be particularly impactful.
“There has been significant progress in increasing life expectancy and advancing medical science, making this an opportune moment to contribute meaningfully,” he says. “We anticipate more public attention to longevity via foreseeable technology breakthroughs.”
Immortal Dragons officially launched around 18 months ago and currently manages $40 million in assets, primarily at the seed and pre-seed stages, with a soft cap at $100 million valuations. The company has already made several investments, including longevity biotechs such as Frontier Bio and Unlimited Bio.
“We function more like a corporate venture capital fund, with only one external limited partner,” says Boyang, who is also a senior venture fellow at US-based longevity investment fund Healthspan Capital. “Most of the money we invest is our own, which gives us the flexibility to make quick decisions and invest in projects we’re passionate about.”
Purpose-driven investment
When it comes to Immortal Dragons’ “purpose-driven” investment philosophy, Boyang highlights his fund’s mission: to prioritize impact rather than financial return.
“If we were solely chasing financial returns, we’d be better off handing our money to fund managers with a deep understanding of pharma and drug discovery,” he says. “Instead, we identify and support projects that might otherwise struggle to secure funding. These are often underfunded “moonshot” opportunities, such as controversial or high-risk projects with low success rates but transformative potential. We deliberately avoid playing the conventional games of big pharma, instead focusing on areas where we can make a meaningful difference.”
The fund’s investment strategy rests on several key pillars. The first focuses on “replacement strategy” and involves betting on radical, frontier science, including part replacement technologies, 3D bioprinting, xenotransplantation and whole-body replacement.
“The human body is incredibly complex, with countless ways for things to go wrong. Instead of tackling each problem individually, a replacement strategy could involve creating new organs, tissues, or even plasma.” says Boyang, “A broken smartphone will often need part replacements instead of repair, so we support moonshot companies working to bring meaningful replacement breakthroughs to human biology.”
The second pillar is the development of infrastructure to support experimentation and clinical advancement. This includes initiatives like Vitalia, a special economic zone initiative seeking to provide a regulatory sandbox for rapid longevity research.
“Whether it’s cutting-edge science or creating better environments for research, we ask, ‘Will this make an impact?’” explains Boyang. “Our investment in Longevity.Technology aligns with our goal of supporting impactful infrastructure projects. Evangelism and public awareness are critical for longevity, and Longevity.Technology plays a crucial role in raising awareness, so we’re confident in its long-term value.”
A third area of interest to the fund is technology-driven acceleration through tools like artificial intelligence and digital twins. Indeed, Immortal Dragons is working on its own “Digital Twin” project, which Boyang says is a behavioral tool as much as a technological one.
“It’s designed to address the incentive problem by showing people a model of their future health,” he says. “Users can see how their organs might look in 30–40 years based on current habits… By making the consequences of their choices tangible, we hope to boost compliance with healthy behaviors.”
At the end of the day, Boyang says that it all comes back to the fund’s purpose-driven philosophy.
“Whether it’s cutting-edge science or creating better environments for research, we need to see the opportunity for real impact,” he says. “Moonshot projects push the boundaries of science, while infrastructure work – like special economic zones – creates conditions for broader success.”
Overcoming barriers
Still, acknowledges Boyang, the field faces major obstacles, including societal skepticism around life extension.
“Many mistakenly associate longevity efforts with class divides or question their ethical basis,” he says. “Another challenge is the lack of immediate incentives for individuals to pursue longevity solutions. Unlike treating acute illnesses, the benefits of longevity research – such as extending life by 20 years – are harder to grasp.”
However, Boyang remains optimistic and suggests that, as with space or aviation, early pioneers of longevity can trigger a cascade of innovation and participation.
“It takes individuals with a strong instinct or calling – like Elon Musk’s focus on Mars colonization – to bear the high risks and uncertainties, and this is why we invest money and resources, even my own body, as gerontology research advances,” he says, referencing the fact that he is also one of the first 300 global recipients of Minicircle’s follistatin gene therapy. “The gene therapy is a personal attempt, but it reflects our risk profile and support to the cause – we have a strong motivation to support the first wave of longevity companies to make profit, and propel the investment flywheel.”
Longevity.Technology’s Newman concurs. “With the backing of Immortal Dragons, we are accelerating towards a future where longevity is no longer niche – but a mainstream, data-driven, global investment frontier,” he says. “Their bold, future-facing approach to longevity investment resonates with our mission to elevate this sector into a globally recognised and highly investable space. Together, we aim to push boundaries – not only in what longevity means, but in how the industry scales and connects.”
In Q4 2025, Longevity.Technology will launch an agentic AI-powered M&A and investment platform – the first designed specifically for longevity biotech – alongside the public release of proprietary datasets.
“This will allow us to exponentially grow our data-led content and deepen our influence as the central knowledge hub for the sector,” says Newman. “Our events programme, developed with Founder Forum, continues to gain momentum with a wider international rollout planned, and we’re extending the reach of our consumer offering through FLT.life and a social-first content strategy aimed at a broader, more engaged audience.”
Boyang’s final call to action is both modest and ambitious. “At a minimum, people should subscribe to Longevity.Technology and share its insights with others,” he says. “Simply becoming advocates and spreading the word can help build momentum for the sector.”
But beneath this simple recommendation lies a larger vision: that society must begin to see aging not as fate, but as a challenge worth overcoming.
“People should have the choice to live longer if they want to – life extension is an infinite game that we might not win in this generation, but we will make sure we pass on the torch,” says Boyang. “We want to push boundaries and see breakthroughs, and our philosophy underpins everything we do.”
Expression of interest
If you are interested in joining Longevity.Technology’s seed round, which is closing soon, please let us know here:
Photographs courtesy of Immortal Dragons.
Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. First Longevity is targeted exclusively at sophisticated investors who understand these risks and make their own investment decisions. Investment opportunities have not been approved as financial promotions and are not covered by the Financial Services Compensation Scheme (FSCS) and you may not have access to the Financial Ombudsman Service (FOS). If you are in any doubt about the action you should take or the contents of any of the Financial Promotion received, you should contact your stockbroker, solicitor, accountant, bank manager or other professional adviser authorised under the Financial Services and Markets Act 2000, who specialises in advising on bonds, shares and other securities, including unlisted securities.
Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status.
The post Inside the longevity fund that aims to ‘make death optional’ appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
